

Carolyn A Young

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8016778/publications.pdf>

Version: 2024-02-01

117
papers

5,187
citations

109137

35
h-index

95083

68
g-index

117
all docs

117
docs citations

117
times ranked

5857
citing authors

#	ARTICLE	IF	CITATIONS
1	Flexibility to manage and enhance quality of life among people with motor neurone disease. <i>Disability and Rehabilitation</i> , 2022, 44, 2752-2762.	0.9	3
2	Medical therapies for amyotrophic lateral sclerosis-related respiratory decline: an appraisal of needs, opportunities and obstacles. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2022, 23, 66-75.	1.1	1
3	Fatigue and anxiety mediate the effect of dyspnea on quality of life in amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2022, 23, 390-398.	1.1	4
4	The four self-efficacy trajectories among people with multiple sclerosis: Clinical associations and implications. <i>Journal of the Neurological Sciences</i> , 2022, 436, 120188.	0.3	3
5	Experience of telehealth in people with motor neurone disease using noninvasive ventilation. <i>Disability and Rehabilitation: Assistive Technology</i> , 2021, 16, 490-496.	1.3	20
6	Measuring coping in people with amyotrophic lateral sclerosis using the Coping Index-ALS: A patient derived, Rasch compliant scale. <i>Journal of the Neurological Sciences</i> , 2021, 421, 117285.	0.3	0
7	Quality of life in multiple sclerosis is dominated by fatigue, disability and self-efficacy. <i>Journal of the Neurological Sciences</i> , 2021, 426, 117437.	0.3	19
8	Letter to the editor re: the effect of pelvic floor exercise program on incontinence and sexual dysfunction in multiple sclerosis patients Altunan et al., <i>IJUN</i> , (2021) 53:1059. <i>International Urology and Nephrology</i> , 2021, 53, 2297-2298.	0.6	0
9	Understanding quality of life across different clinical subtypes of multiple sclerosis: a thematic analysis. <i>Quality of Life Research</i> , 2021, , 1.	1.5	4
10	Do pain, anxiety and depression influence quality of life for people with amyotrophic lateral sclerosis/motor neuron disease? A national study reconciling previous conflicting literature. <i>Journal of Neurology</i> , 2020, 267, 607-615.	1.8	25
11	The Edinburgh Cognitive and Behavioral ALS Screen (ECAS) in frontotemporal dementia. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2020, 21, 606-613.	1.1	7
12	Effect of Short-term Integrated Palliative Care on Patient-Reported Outcomes Among Patients Severely Affected With Long-term Neurological Conditions. <i>JAMA Network Open</i> , 2020, 3, e2015061.	2.8	26
13	Pharmacological treatment for chronic central neuropathic pain in people with multiple sclerosis. <i>The Cochrane Library</i> , 2020, , .	1.5	1
14	Is NIPA1-associated hereditary spastic paraplegia always "pure"? Further evidence of motor neurone disease and epilepsy as rare manifestations. <i>Neurogenetics</i> , 2020, 21, 305-308.	0.7	7
15	The WHOQOL-BREF: a modern psychometric evaluation of its internal construct validity in people with multiple sclerosis. <i>Quality of Life Research</i> , 2020, 29, 1961-1972.	1.5	15
16	Measuring quality of life in ALS/MND: validation of the WHOQOL-BREF. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2020, 21, 364-372.	1.1	5
17	Letter to the editor re: Worsening disability status in multiple sclerosis predicts urologic complications. <i>Int Urol Nephrol</i> . May; 52(5):859-863. doi: 10.1007/s11255-020-02381-6. Epub 2020 Jan 25 by Abello et al. <i>International Urology and Nephrology</i> , 2020, 52, 2307-2308.	0.6	0
18	Immediate versus delayed short-term integrated palliative care for advanced long-term neurological conditions: the OPTCARE Neuro RCT. <i>Health Services and Delivery Research</i> , 2020, 8, 1-80.	1.4	4

#	ARTICLE	IF	CITATIONS
19	Health Utilities and Costs for Motor Neurone Disease. <i>Value in Health</i> , 2019, 22, 1257-1265.	0.1	17
20	Exploring and Addressing "Concerns"™ for Significant Others to Extend the Understanding of Quality of Life With Amyotrophic Lateral Sclerosis: A Qualitative Study. <i>Journal of Central Nervous System Disease</i> , 2019, 11, 117957351985936.	0.7	9
21	The relationships between symptoms, disability, perceived health and quality of life in amyotrophic lateral sclerosis/motor neuron disease. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2019, 20, 317-327.	1.1	27
22	Use of coping strategies in MND/ALS: Association with demographic and disease-related characteristics. <i>Acta Neurologica Scandinavica</i> , 2019, 140, 131-139.	1.0	1
23	Incorporating self-reported questions for telemonitoring to optimize care of patients with MND on noninvasive ventilation (MND OptNIVent). <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2019, 20, 336-347.	1.1	11
24	Development and validation of Spasticity Index-Amyotrophic Lateral Sclerosis. <i>Acta Neurologica Scandinavica</i> , 2018, 138, 47-54.	1.0	7
25	Treatment of fatigue in amyotrophic lateral sclerosis/motor neuron disease. <i>The Cochrane Library</i> , 2018, 2018, CD011005.	1.5	22
26	Quality of life for post-polio syndrome: a patient derived, Rasch standard scale. <i>Disability and Rehabilitation</i> , 2018, 40, 597-602.	0.9	4
27	Risk factors for social withdrawal in amyotrophic lateral sclerosis/motor neurone disease. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2018, 19, 591-598.	1.1	11
28	Mapping ALSFRS-R and ALSUI to EQ-5D in Patients with Motor Neuron Disease. <i>Value in Health</i> , 2018, 21, 1322-1329.	0.1	9
29	Symptomatic treatments for amyotrophic lateral sclerosis/motor neuron disease. <i>The Cochrane Library</i> , 2017, 2017, CD011776.	1.5	39
30	Comparison of the King's™ and MiToS staging systems for ALS. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2017, 18, 227-232.	1.1	58
31	Sexual functioning in multiple sclerosis: Relationships with depression, fatigue and physical function. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1268-1275.	1.4	24
32	Economic Studies in Motor Neurone Disease: A Systematic Methodological Review. <i>Pharmacoeconomics</i> , 2017, 35, 397-413.	1.7	5
33	Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials. <i>Neurology</i> , 2017, 89, 1915-1922.	1.5	82
34	Rasch analysis of SF-36™ Qualiveen in multiple sclerosis. <i>Neurourology and Urodynamics</i> , 2017, 36, 1161-1166.	0.8	14
35	A multicentre evaluation of oropharyngeal secretion management practices in amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2017, 18, 1-9.	1.1	20
36	The Neurological Sleep Index: A suite of new sleep scales for multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2016, 2, 205521731664226.	0.5	3

#	ARTICLE	IF	CITATIONS
37	How integrated are neurology and palliative care services? Results of a multicentre mapping exercise. <i>BMC Neurology</i> , 2016, 16, 63.	0.8	41
38	Systematic review of the influence of spasticity on quality of life in adults with chronic neurological conditions. <i>Disability and Rehabilitation</i> , 2016, 38, 1431-1441.	0.9	44
39	Spasticity in multiple sclerosis: Associations with impairments and overall quality of life. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 5, 34-39.	0.9	46
40	The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 520-532.	1.4	34
41	Why don't they accept non-invasive ventilation?: Insight into the interpersonal perspectives of patients with motor neurone disease. <i>British Journal of Health Psychology</i> , 2015, 20, 341-359.	1.9	31
42	Regionality of disease progression predicts prognosis in amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2015, 16, 442-447.	1.1	3
43	Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. <i>Practical Neurology</i> , 2015, 15, 273-279.	0.5	169
44	Use of clinical staging in amyotrophic lateral sclerosis for phase 3 clinical trials. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 45-49.	0.9	75
45	Experience of long-term use of non-invasive ventilation in motor neuron disease: an interpretative phenomenological analysis. <i>BMJ Supportive and Palliative Care</i> , 2014, 4, 50-56.	0.8	19
46	Treatment for fatigue in amyotrophic lateral sclerosis/motor neuron disease (ALS/MND). <i>The Cochrane Library</i> , 2014, , .	1.5	2
47	Health utility decreases with increasing clinical stage in amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2014, 15, 285-291.	1.1	26
48	Achieving Saturation in Thematic Analysis: Development and Refinement of a Codebook. <i>Comprehensive Psychology</i> , 2014, 3, 03.CP.3.4.	0.3	275
49	Assessing social isolation in motor neurone disease: A Rasch analysis of the MND Social Withdrawal Scale. <i>Journal of the Neurological Sciences</i> , 2013, 334, 112-118.	0.3	8
50	Management of sialorrhoea in motor neuron disease: A survey of current UK practice. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2013, 14, 521-527.	1.1	28
51	Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1074-1083.	1.4	87
52	Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2013, 12, 339-345.	4.9	118
53	Perceived changes and minimum clinically important difference of the Neurological Fatigue Index for multiple sclerosis (NFI-MS). <i>Multiple Sclerosis Journal</i> , 2013, 19, 502-505.	1.4	19
54	Poststroke Fatigue: The Patient Perspective. <i>Topics in Stroke Rehabilitation</i> , 2013, 20, 478-484.	1.0	23

#	ARTICLE	IF	CITATIONS
55	Determinants of accepting non-invasive ventilation treatment in motor neurone disease: a quantitative analysis at point of need. <i>Health Psychology and Behavioral Medicine</i> , 2013, 1, 47-58.	0.8	16
56	The impact of fatigue and psychosocial variables on quality of life for patients with motor neuron disease. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2013, 14, 537-545.	1.1	31
57	Is the Epworth Sleepiness Scale Suitable for Use in Stroke?. <i>Topics in Stroke Rehabilitation</i> , 2013, 20, 493-499.	1.0	13
58	Rasch analysis of the WHOQOL-BREF in post polio syndrome. <i>Journal of Rehabilitation Medicine</i> , 2013, 45, 873-880.	0.8	14
59	The patient experience of fatigue in motor neurone disease. <i>Frontiers in Psychology</i> , 2013, 4, 788.	1.1	29
60	Tumefactive demyelination: an unusual cause of a spontaneously resolving homonymous hemianopia. <i>BMJ Case Reports</i> , 2013, 2013, bcr2013009363-bcr2013009363.	0.2	3
61	The unidimensional self-efficacy scale for MS (USE-MS): developing a patient based and patient reported outcome. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1326-1333.	1.4	25
62	Assessing and managing depression and fatigue in motor neuron disease. <i>Neurodegenerative Disease Management</i> , 2012, 2, 401-409.	1.2	3
63	Validation of the Neurological Fatigue Index for stroke (NFI-Stroke). <i>Health and Quality of Life Outcomes</i> , 2012, 10, 51.	1.0	24
64	Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. <i>PLoS ONE</i> , 2012, 7, e38661.	1.1	35
65	Adverse cognitive effects of phenytoin in severe brain injury: A case report. <i>Brain Injury</i> , 2011, 25, 634-637.	0.6	5
66	Treatment for sialorrhoea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis. <i>The Cochrane Library</i> , 2011, , CD006981.	1.5	32
67	Development of a patient reported outcome measure for fatigue in motor neurone disease: the Neurological Fatigue Index (NFI-MND). <i>Health and Quality of Life Outcomes</i> , 2011, 9, 101.	1.0	31
68	Protocol for a double-blind randomised placebo-controlled trial of lithium carbonate in patients with amyotrophic Lateral Sclerosis (LiCALS) [Eudract number: 2008-006891-31]. <i>BMC Neurology</i> , 2011, 11, 111.	0.8	16
69	Rasch analysis of the hospital anxiety and depression scale (hads) for use in motor neurone disease. <i>Health and Quality of Life Outcomes</i> , 2011, 9, 82.	1.0	96
70	The relationship between fatigue and other clinical features of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2011, 17, 604-612.	1.4	83
71	Factors predisposing to the development of multiple sclerosis. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2011, 104, 383-386.	0.2	19
72	Development of a patient reported outcome scale for fatigue in multiple sclerosis: The Neurological Fatigue Index (NFI-MS). <i>Health and Quality of Life Outcomes</i> , 2010, 8, 22.	1.0	88

#	ARTICLE	IF	CITATIONS
73	Rasch analysis of the Modified Fatigue Impact Scale (MFIS) in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 1049-1051.	0.9	76
74	Central trigeminal involvement in multiple sclerosis using high-resolution MRI at 3 T. <i>British Journal of Radiology</i> , 2010, 83, 493-498.	1.0	53
75	Disability after encephalitis: development and validation of a new outcome score. <i>Bulletin of the World Health Organization</i> , 2010, 88, 584-592.	1.5	50
76	P156 Does analysis of patient-ventilator interaction offer benefits in addition to overnight pulse oximetry in patients with motor neurone disease being followed on non-invasive ventilation?. <i>Thorax</i> , 2010, 65, A144-A144.	2.7	0
77	Bladder symptoms in multiple sclerosis: a review of pathophysiology and management. <i>Expert Opinion on Drug Safety</i> , 2010, 9, 905-915.	1.0	18
78	Identifying poor adaptation to a new diagnosis of motor neuron disease: A pilot study into the value of an early patient-led interview. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2010, 11, 104-109.	2.3	13
79	The effects of an 'exercise and education' programme on exercise self-efficacy and levels of independent activity in adults with acquired neurological pathologies: an exploratory, randomized study. <i>Clinical Rehabilitation</i> , 2009, 23, 371-383.	1.0	25
80	Rasch analysis of the Fatigue Severity Scale in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009, 15, 81-87.	1.4	95
81	Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2009, 374, 1503-1511.	6.3	551
82	Anticholinergics for urinary symptoms in multiple sclerosis. , 2009, , CD004193.		50
83	A randomized group intervention trial to enhance mood and self-efficacy in people with multiple sclerosis. <i>British Journal of Health Psychology</i> , 2008, 13, 619-631.	1.9	45
84	Vitamin D receptor gene polymorphism is associated with reduced disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2008, 14, 1280-1283.	1.4	34
85	Sporadic Creutzfeldt Jakob disease in two adolescents. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008, 79, 14-18.	0.9	16
86	Perceptions of goal setting in a neurological rehabilitation unit: A qualitative study of patients, carers and staff. <i>Acta Dermato-Venereologica</i> , 2008, 40, 190-194.	0.6	45
87	A medical definition of fatigue in multiple sclerosis. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2007, 101, 49-60.	0.2	132
88	Studies of associations between disability in multiple sclerosis, skin type, gender and ultraviolet radiation. <i>Multiple Sclerosis Journal</i> , 2007, 13, 369-375.	1.4	27
89	Perceptions of self-efficacy and rehabilitation among neurologically disabled adults. <i>Clinical Rehabilitation</i> , 2007, 21, 230-240.	1.0	76
90	Minocycline for amyotrophic lateral sclerosis or motor neuron disease. <i>The Cochrane Library</i> , 2007, , .	1.5	1

#	ARTICLE	IF	CITATIONS
91	Validation and Reliability of the Neuropathic Pain Scale (NPS) in Multiple Sclerosis. <i>Clinical Journal of Pain</i> , 2007, 23, 473-481.	0.8	40
92	Oromucosal δ^9 -tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: An uncontrolled, open-label, 2-year extension trial. <i>Clinical Therapeutics</i> , 2007, 29, 2068-2079.	1.1	173
93	Detection of hearing impairment and handicap in Paget's disease of bone using a simple scoring system: A case control study. <i>Bone</i> , 2007, 40, 189-193.	1.4	10
94	Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial. <i>Multiple Sclerosis Journal</i> , 2007, 13, 502-508.	1.4	53
95	Treatment for ataxia in multiple sclerosis. <i>The Cochrane Library</i> , 2007, , CD005029.	1.5	77
96	3D MRI in multiple sclerosis: a study of three sequences at 3 T. <i>British Journal of Radiology</i> , 2007, 80, 307-320.	1.0	16
97	How does current care practice influence the experience of a new diagnosis of motor neuron disease? A qualitative study of current guidelines-based practice. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2006, 7, 161-166.	2.3	32
98	Circle of Willis variation in a complex stroke presentation: a case report. <i>BMC Neurology</i> , 2006, 6, 13.	0.8	0
99	Worries and concerns of patients with multiple sclerosis: development of an assessment scale. <i>Multiple Sclerosis Journal</i> , 2006, 12, 196-203.	1.4	30
100	A randomized controlled trial of a health promotion education programme for people with multiple sclerosis. <i>Clinical Rehabilitation</i> , 2006, 20, 783-792.	1.0	72
101	Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. <i>Neurology</i> , 2005, 65, 812-819.	1.5	583
102	Assessment of health needs in multidisciplinary care. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2003, 74, 5-5.	0.9	1
103	Development and validation of a self-efficacy measure for people with multiple sclerosis: the Multiple Sclerosis Self-efficacy Scale. <i>Multiple Sclerosis Journal</i> , 2003, 9, 73-81.	1.4	85
104	A randomised controlled trial comparing rehabilitation against standard therapy in multiple sclerosis patients receiving intravenous steroid treatment. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2003, 74, 1225-1230.	0.9	121
105	A randomised placebo controlled exploratory study of vitamin B-12, lofepramine, and L-phenylalanine (the "Cari Loder regime") in the treatment of multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2002, 73, 246-249.	0.9	61
106	Quality of life issues in motor neurone disease: the development and validation of a coping strategies questionnaire, the MND Coping Scale. <i>Journal of the Neurological Sciences</i> , 2001, 191, 79-85.	0.3	35
107	HLA-DRB1 and disease outcome in multiple sclerosis. <i>Journal of Neurology</i> , 2001, 248, 304-310.	1.8	56
108	Measuring the impact of multiple sclerosis on psychosocial functioning: the development of a new self-efficacy scale. <i>Clinical Rehabilitation</i> , 2001, 15, 259-265.	1.0	53

#	ARTICLE	IF	CITATIONS
109	Multiple sclerosis: Care needs for 2000 and beyond. <i>Journal of the Royal Society of Medicine</i> , 2000, 93, 219-224.	1.1	14
110	The role of affect on the perception of disability in multiple sclerosis. <i>Clinical Rehabilitation</i> , 2000, 14, 50-54.	1.0	61
111	Development of a patient-specific dyspnoea questionnaire in motor neurone disease (MND): the MND dyspnoea rating scale (MDRS). <i>Journal of the Neurological Sciences</i> , 2000, 180, 86-93.	0.3	19
112	Quality of life assessment in MND: development of a Social Withdrawal Scale. <i>Journal of the Neurological Sciences</i> , 1999, 169, 26-34.	0.3	24
113	Building a care and research team. <i>Journal of the Neurological Sciences</i> , 1998, 160, S137-S140.	0.3	23
114	Assessment of depression in patients with motor neuron disease and other neurologically disabling illness. <i>Journal of the Neurological Sciences</i> , 1997, 152, s75-s79.	0.3	66
115	Obstructive sleep apnoea with Arnold-Chiari malformation.. <i>Thorax</i> , 1995, 50, 690-697.	2.7	33
116	Disease progression and perceptions of health in patients with motor neurone disease. <i>Journal of the Neurological Sciences</i> , 1995, 129, 50-53.	0.3	21
117	Opsoclonus-myooclonus syndrome: an autopsy study of three cases. <i>The European Journal of Medicine</i> , 1993, 2, 239-41.	0.1	3